Anteris Technologies Ltd

ASX AVR.AX

Anteris Technologies Ltd Cash and Short-Term Investments for the year ending December 31, 2023: USD 21.00 M

Anteris Technologies Ltd Cash and Short-Term Investments is USD 21.00 M for the year ending December 31, 2023, a 123.19% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Anteris Technologies Ltd Cash and Short-Term Investments for the year ending December 31, 2022 was USD 9.41 M, a -39.25% change year over year.
Anteris Technologies Ltd Cash and Short-Term Investments for the year ending December 31, 2021 was USD 15.49 M, a 361.88% change year over year.
Anteris Technologies Ltd Cash and Short-Term Investments for the year ending December 31, 2020 was USD 3.35 M, a -70.33% change year over year.
Anteris Technologies Ltd Cash and Short-Term Investments for the year ending December 31, 2019 was USD 11.30 M, a 33.31% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

ASX: AVR.AX

Anteris Technologies Ltd

CEO	Mr. Wayne Geoffrey Paterson
IPO Date	March 22, 2004
Location	Australia
Headquarters	Toowong Tower
Employees	1
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Composite Materials Medical Instruments Pharmaceuticals Plastics

Description

Anteris Technologies Ltd operates as a structural heart company. It manufactures and sells ADAPT, a regenerative tissue product. The company also engages in the developing of DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. In addition, it researches and develops regenerative medicines. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.

Key trends

Past 5 years